NASDAQ:APLM Apollomics Q2 2026 Earnings Results & Report $16.37 -0.08 (-0.49%) As of 02:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Apollomics reported Q2 2026 earnings on November 6, 2026. The company reported EPS of -$2.02. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateNovember 6, 2026TimeAfter Market Closes Apollomics EPS ResultsActual EPS-$2.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AApollomics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Apollomics Q2 2026 Earnings FAQ Did Apollomics beat earnings estimates for Q2 2026? Apollomics (NASDAQ:APLM) reported earnings of -$2.02 per share for Q2 2026. The report was announced on Friday, November 6, 2026. Apollomics Earnings HeadlinesApollomics Reports First-Half 2026 Financial ResultsNovember 9, 2026 | markets.businessinsider.comApollomics Inc - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)Apollomics IncAugust 18, 2026 | markets.ft.comApollomics Announces $10 Million Private Placement TransactionAugust 11, 2026 | globenewswire.comApollomics Inc. Class AAugust 10, 2026 | edition.cnn.comSee More Apollomics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apollomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apollomics and other key companies, straight to your email. Email Address About ApollomicsApollomics (NASDAQ:APLM) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer, with an emphasis on targeted therapies and immuno-oncology. The company has operated in the United States and China. Its lead candidate, vebreltinib (APL-101), is an investigational, selective inhibitor of the MET protein being studied in cancers with alterations in the MET pathway, including certain lung cancers. Apollomics has also described additional investigational oncology candidates in its pipeline. Apollomics’ drug candidates are in development and are not approved medicines. The company was founded in 2015; its programs are intended to address cancers for which existing treatment options may be limited.View Apollomics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.